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Mipomersen is a 20mer antisense oligonucleotide (ASO) that inhibits apolipoprotein B (apoB) synthesis; its low-
density lipoprotein (LDL)–lowering effects should therefore result from reduced secretion of very-low-density lipo-
protein (VLDL). We enrolled 17 healthy volunteers who received placebo injections weekly for 3 weeks
followed by mipomersen weekly for 7 to 9 weeks. Stable isotopes were used after each treatment to determine
fractional catabolic rates and production rates of apoB in VLDL, IDL (intermediate-density lipoprotein), and LDL, and
of triglycerides in VLDL. Mipomersen significantly reduced apoB in VLDL, IDL, and LDL, which was associated with
increases in fractional catabolic rates of VLDL and LDL apoB and reductions in production rates of IDL and LDL
apoB. Unexpectedly, the production rates of VLDL apoB and VLDL triglycerides were unaffected. Small interfering
RNA–mediated knockdown of apoB expression in human liver cells demonstrated preservation of apoB secretion
across a range of apoB synthesis. Titrated ASO knockdown of apoBmRNA in chow-fed mice preserved both apoB
and triglyceride secretion. In contrast, titrated ASO knockdown of apoB mRNA in high-fat–fed mice resulted in
stepwise reductions in both apoB and triglyceride secretion. Mipomersen lowered all apoB lipoproteins without
reducing the production rate of either VLDL apoB or triglyceride. Our human data are consistent with long-
standing models of posttranscriptional and posttranslational regulation of apoB secretion and are supported
by in vitro and in vivo experiments. Targeting apoB synthesis may lower levels of apoB lipoproteins without nec-
essarily reducing VLDL secretion, thereby lowering the risk of steatosis associated with this therapeutic strategy..
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Dyslipidemia, a major risk factor for cardiovascular disease (CVD), is
characterized by elevated levels of apolipoprotein B100 (apoB) lipo-
proteins, including very-low-density lipoproteins (VLDL), carrying both
triglycerides (TGs) and cholesterol, and low-density lipoproteins (LDL)
carrying cholesterol (1). Although there is some heterogeneity in pub-
lished results, increased secretion of apolipoprotein B (apoB) lipo-
proteins, particularly VLDL, is the characteristic abnormality observed
in people with dyslipidemia (2, 3). On the basis of numerous clinical
trials, however, lowering LDL cholesterol (LDL-C) remains the first-
line therapy for reducing risk of CVD in such individuals (4). HMG-CoA
(3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors, better
known as statins, are the most potent drugs available for reducing lev-
els of apoB lipoproteins, mainly LDL, but also, to a lesser degree, VLDL.
Although some studies have shown that statins can reduce production
rates (PRs) of VLDL and LDL apoB, the central actions of statins result
in an increase in the number of LDL receptors (LDLR) at the plas-
ma membranes of cells, particularly the liver (5). More than 10% of
individuals receiving statins are, however, clinically intolerant to
these agents or can only take low doses of statin because of drug-
specific side effects (6). Thus, about 50% of the patients on maximally
tolerated statin therapy do not reach the recommended LDL-C levels
established by National Cholesterol Education Program Adult Treat-1Columbia University College of Physicians and Surgeons, 630 West 168th Street, New York,
NY 10032, USA. 2Biological Sciences Department, New York City College of Technology,
300 Jay Street, Brooklyn, NY 11201, USA. 3Sanofi-Genzyme, 500 Kendall Street, Cambridge,
MA 02142, USA.
*Corresponding author. E-mail: gr2104@cumc.columbia.edu (G.R.-S.); hng1@cumc.
columbia.edu (H.N.G.)
†Present address: Ironwood Pharmaceuticals, 301 Binney Street, Cambridge, MA
02142, USA.
www.Sciencment Panel III guidelines, especially patients with genetic lipid disor-
ders such as familial hypercholesterolemia (7). Interest remains high,
therefore, in the development of other therapeutic approaches to re-
duce circulating levels of apoB lipoproteins.
Two such agents—one a small-molecule inhibitor of microsomal
triglyceride transfer protein (MTP) (8) and the other a second-generation
antisense oligonucleotide (ASO) to apoB (9)—were recently approved
by the U.S. Food and Drug Administration (FDA) for patients with
homozygous familial hypercholesterolemia. Despite the ability of both
drugs to reduce apoB lipoproteins, there are concerns about the occur-
rence of hepatic steatosis. Preclinical studies in rodents with either an
ASO against MTP or small-molecule MTP inhibitors resulted in sig-
nificant increases in liver TG levels (10, 11). This adverse effect was
confirmed in studies of homozygous familial hypercholesterolemia pa-
tients with the recently approvedMTP inhibitor, lomitapide (JUXTAPID,
Aegerion) (8, 12). In preclinical studies in mice treated with ASO to
apoB, there was no hepatic steatosis (10, 13), although increased liver
TG has been observed in clinical trials of patients receiving mipomersen
(KYNAMRO, Sanofi-Genzyme)—a fully phosphorothioate 20mer oligo-
nucleotide with 5 2′-methoxyethyl residues at the 5′ and 3′ poles and
a 10 deoxynucleotide center—for as long as 26 weeks for the treatment
of familial hypercholesterolemia (14, 15). A combined analysis of three
randomized trials with mipomersen treatment of patients with familial
hypercholesterolemia indicated stabilization of steatosis during long-
term treatment of more than 2 years. Reversal to baseline levels of hepatic
fat was demonstrated in a subset of about 25% of participants who
had magnetic resonance imaging performed 24 weeks after cessation
of treatment (16).
The unique mechanisms of lomitapide or mipomersen to inhibit apoB
production could explain the marked differences in the accumulationeTranslationalMedicine.org 27 January 2016 Vol 8 Issue 323 323ra12 1
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 of hepatic TG that have been observed in mice. When lomitapide in-
hibits MTP, the absence of transfer of TG, as well as phospholipids
and cholesteryl esters, from the endoplasmic reticulum (ER) membrane
to nascent apoB leads to degradation of apoB and the absence of lipid
droplets in the ER lumen (17). In contrast, when apoB synthesis is sub-
maximally inhibited, MTP is still able to transfer ER membrane lipids
to apoB that escaped inhibition and was synthesized. This would be the
case with the 200 mg/week dose of mipomersen that has been ap-
proved for patients with homozygous familial hypercholesterolemia as
an adjunct to lipid-lowering medications and diet (18, 19). With the
current dose of mipomersen used clinically, there could be increased
“loading” of TG onto each apoB that is synthesized, resulting in the
assembly and secretion of larger VLDL carrying more TG per particle.
Evidence supporting the ability of the liver to vary the amount of
TG incorporated into nascent VLDL derives from studies of mice with
increased de novo lipogenesis (20) and humans on high-carbohydrate
diets (21) or with hepatic steatosis (22). This mechanism, which could
compensate for reduced synthesis of apoB, would be unlikely to occur
with inhibition of MTP, which is absolutely essential for the transfer of
TG onto nascent apoB. An alternative or additional compensatory re-
sponse to mipomersen-mediated decreases in the synthesis of apoB is
suggested by many studies in hepatocytes demonstrating that only a por-
tion of newly synthesized apoB is secreted, with the availability of hepatic
lipids, particularly TG, being the major determinant of whether nascent
apoB is secreted or degraded (17). In this model, submaximal inhibition
of apoB synthesis might be compensated for by increasing the propor-
tion of newly synthesized apoB that is secreted, thereby maintaining
hepatic lipid homeostasis.
Here, we examined the effects of mipomersen treatment on frac-
tional catabolic rates (FCRs) and PRs of apoB-containing lipoproteins
and VLDL TG, as well as on hepatic de novo lipogenesis, in healthy
volunteers. We also conducted studies of apoB and TG secretion during
inhibition of apoB synthesis in a human hepatoma line and in mice.
Our hypothesis was that mipomersen would decrease VLDL apoB PR,
whereas VLDL TG PR would be unchanged, indicating the assembly
and secretion of larger, TG-enriched VLDL particles. If our hypothesis is
correct, mipomersen therapy could lower the levels of apoB-containing
lipoproteins without necessarily causing significant hepatic steatosis.016RESULTS
Effects of mipomersen on lipid and apoB levels
Thirty-one subjects were screened, 20 enrolled, and 8 healthy men and
9 healthy women completed the study (table S1). Baseline character-
istics are in Table 1. Participants were not taking medications known
to affect lipid metabolism and had normal plasma glucose levels and
normal hepatic and renal function. They received three weekly doses
of placebo followed by seven weekly doses of mipomersen treatment
(fig. S1). Mipomersen treatment resulted in significant reductions in
plasma levels of total cholesterol, TG, LDL-C, and apoB, but not high-
density lipoprotein cholesterol (HDL-C) (Table 2). The cholesterol
and TG concentrations in VLDL, IDL, and LDL were decreased sig-
nificantly by mipomersen treatment (Fig. 1, A and B), and there were
marked reductions in the levels of VLDL apoB (−29%), IDL apoB
(−25%), and LDL apoB (−42%) (Fig. 1C). We observed reductions
in VLDL, IDL, and LDL particle numbers as determined by ion mo-
bility (23) (table S2).www.SciencEffects of mipomersen on apoB metabolism in VLDL, IDL,
and LDL
The reduction in VLDL apoB concentration during mipomersen
treatment compared to placebo (Fig. 1C) was due to a 23% increase
in the median FCR of VLDL apoB (Table 3). There was no significant
effect of mipomersen treatment on VLDL apoB PR. The percent of
VLDL apoB converted to IDL declined from 70 to 58%. This change,
which reflects direct removal of VLDL apoB from plasma during
mipomersen treatment, was associated with a significant 33% reduc-
tion in IDL apoB PR (Table 3) associated with the significant re-
duction in IDL apoB level (Fig. 1C) on mipomersen.
The FCR of IDL apoB did not change, and there was no effect of
mipomersen on the conversion of IDL apoB to LDL (76 and 74%,
respectively) (Table 3). However, the reduced IDL apoB PR, together
with a modest fall in the secretion of LDL-like particles directly from
the liver, resulted in a significant fall in LDL apoB concentration (Fig. 1C)
owing to a 27% reduction in mean LDL apoB PR on mipomersen
(Table 3). There was no significant change in total apoB PR (sum of VLDL
apoB PR and direct LDL apoB PR) on mipomersen (Table 3).
The marked fall in LDL apoB levels during mipomersen therapy
(Fig. 1C) was due not only to decreased PR but unexpectedly to a
30% increase in the FCR of LDL apoB (Table 3). Because circulatingTable 1. Subject baseline characteristics. Twenty individuals were
enrolled and 17 completed the study (table S1).Mean age, years (±SD)eTranslationalMedicine.org 27 January 2016 Vol 8 Issue 323 343.5 (14.2)Gender, n (%)Male 8 (47.1)Female 9 (52.9)Race (%)White 29.4Black 47.1Asian 5.9Unknown/mixed race 17.6Mean BMI (±SD) 27.6 (3.2)Table 2. Plasma lipid levels after 3 weeks of placebo and 7 weeks of
mipomersen treatment. Data are means (±SD) of one sample obtained
from each subject (n = 17) just before the kinetic study in each period. Per-
cent change is based on the difference between levels during mipomersen
treatment and during placebo treatment for each subject. The significance
of percent change for each endpoint was examined by paired t test after





(%)23rP valueTotalcholesterol 187.2 (25.7) 132.4 (29.7) −28.6 (16.1) <0.001TG 86.9 (49.3) 57.1 (30.4) −28.0 (28.0) <0.001LDL-C 114.7 (22.3) 61.9 (24) −45.5 (18.9) <0.001ApoB 69.6 (18.9) 40.8 (14.1) −40.3 (17.5) <0.001HDL-C 55.2 (14.3) 59.1 (17.9) 6.8 (19.3) 0.17a12 2
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 proprotein convertase subtilisin/kexin type 9 (PCSK9) is an impor-
tant regulator of hepatic LDLR (24), we quantified this protein in
plasma. There was no significant effect of mipomersen on circulat-
ing concentrations of PCSK9 (261.7 ± 63.6 ng/ml on placebo versus
241.2 ± 58.2 ng/ml on mipomersen) (P = 0.57; paired t test). Altera-
tions in LDL particle size, particularly leading to a greater proportion
of medium-size particles, could increase affinity for the LDL receptor
(25). However, mipomersen treatment was associated with a shift in the
distribution of LDL toward small particles (table S3). Conversely, re-
ductions in the numbers of all larger-size LDL subfractions (table S4)
suggested increased numbers of LDL receptors during administration
of mipomersen, with preferential removal of larger particles. Changes in
hepatic cholesterol balances could alter LDL receptor levels: mipomersen
had no effects on plasma levels of lathosterol, a marker of cholesterol
synthesis, or either campesterol or b-sitosterol, both markers of cho-
lesterol absorption (table S5).
Changes in FCRs of VLDL and LDL could have been affected by
mipomersen-mediated changes in apoC-III or apoE concentrations.www.SciencThere were no changes in plasma apoE levels from placebo (4.9 ±
1.5 mg/dl) to mipomersen treatment (4.5 ± 1.3 mg/dl) (P = 0.2;
paired t test). In contrast, there was a fall in plasma apoC-III of
20% from placebo (9.3 ± 2.7) to mipomersen (7.3 ± 3.2) (P = 0.02;
paired t test).
Effects of mipomersen on VLDL TG metabolism
The concentration of VLDL TG fell by 20% during mipomersen treat-
ment (Fig. 1B). This was accompanied by a 46% increase in the mean
FCR of VLDL TG during mipomersen treatment, with no change seen
in the PR of VLDL TG (Table 3). The percentage of VLDL TG produced
from hepatic de novo lipogenesis did not change (11.2 ± 6.3% and 10.5 ±
5.6% during placebo and mipomersen, respectively) (P = 0.50; paired t
test). To gain insight into the increase in VLDL TG FCR, we measured
post-heparin hepatic lipase (HL) and lipoprotein lipase (LpL) activities
in plasma. Neither of these enzymes was affected bymipomersen treatment
(table S6). Fasting plasma levels of fatty acid (FA) and b-hydroxybutyrate
also did not change between periods (table S6). The individual FCRs
and PRs for VLDL, IDL, and LDL apoB and VLDL TG, for the 17 sub-
jects, are in table S7.
We hypothesized that mipomersen treatment might be associated
with a shift in the size distribution of secreted VLDL, with a larger
TG-rich VLDL entering the circulation. The ratio of PRs of VLDL TG
to VLDL apoB, which should reflect the size of newly secreted VLDL
particles, increased by a median value of 17%, indicating assembly and
secretion of larger VLDL (Table 3). These data were supported by a
significant increase of 25% in the ratio of TG/apoB in circulating
VLDL during mipomersen treatment (Table 3).
Effects of siRNA knockdown of APOB in HepG2 cells on
apoB secretion
To better understand the lack of effect of mipomersen on the secretion
of VLDL apoB in vivo, we examined the effects of the knockdown of
APOB on the secretion of apoB in the human hepatoma cell line HepG2
in vitro. For these studies, we used a small interfering RNA (siRNA)
that has been extensively validated against human APOB in vitro in
HepG2 cells (26) and in vivo in nonhuman primates (27) to titrate the
knockdown of APOB mRNA. We determined that maximal siRNA-
mediated knockdown of APOB mRNA was attained at a concentra-
tion of 10 nM, with about 80% inhibition of apoB synthesis (cell) and
60% inhibition of apoB secretion (media) during a 2-hour steady-state
labeling study compared to a scrambled siRNA control (Fig. 2A). Ti-
tration of the siRNA between 0.05 and 1.0 nM resulted in dose-related
reductions of APOB mRNA (Fig. 2B) and synthesis of the protein in
short-pulse and pulse-chase experiments with or without inhibition of
the proteasome (Fig. 2C). There was an obvious relationship between
increasing siRNA-mediated knockdown of APOB expression and cel-
lular accumulation of newly synthesized apoB in 2-hour labeling studies
(Fig. 2D). However, secretion of apoB remained constant across the
doses of siRNA (Fig. 2E).
When we depicted secretion of apoB as the percent of the total
newly synthesized apoB in cells plus the media after 2 hours of radio-
labeling, there was increased efficiency of secretion (Fig. 2F). In con-
trast, a small-molecule inhibitor of MTP caused parallel decreases in
cellular (Fig. 2G) and secreted (Fig. 2H) apoB after 2 hours of radio-
labeling. Thus, with MTP inhibition, there was no change in the effi-
ciency of secretion of apoB with increasing inhibition of MTP (Fig.
2I). siRNA knockdown of APOB did not affect expression of LDLFig. 1. Effects of mipomersen treatment on human lipoprotein lipids
and apoB levels. Blood samples were obtained from subjects during their
kinetic studies performed after 3 weeks of treatment with placebo and af-
ter 7 weeks of treatment with mipomersen. Plasma was separated from those
samples, and VLDL, IDL, and LDL were isolated by sequential ultracentrifu-
gation. (A and B) Cholesterol and TG were measured by enzymatic methods.
(C) ApoB was determined by commercial enzyme-linked immunosorbent
assay. Data are means ± SD (n = 5 samples obtained from each of the 17 sub-
jects during their two kinetic studies). P values determined by paired t tests
after determining that the data were normally distributed using the Kolmogorov-
Smirnov normality test.eTranslationalMedicine.org 27 January 2016 Vol 8 Issue 323 323ra12 3
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 receptor (LDLR), inducible degrader of the LDLR (IDOL), or PCSK9 in
HepG2 cells (fig. S2).
These results demonstrate that HepG2 cells, under culture condi-
tions where there is very little intracellular TG, are able to accommodate
submaximal reductions in apoB synthesis by increasing the proportion
of newly synthesized apoB that is secreted.
Effect of ASO knockdown of ApoB in mice on secretion of
apoB and TG
To further support the validity of our observation of a lack of effect of
mipomersen on VLDL apoB secretion in normal humans, we per-
formed similar experiments in vivo in Apobec-1 knockout mice, using
a murine-specific ApoB ASO. Apobec-1 knockout mice were used be-
cause they synthesize and secrete only apoB from their livers, making
them more like humans. Mice on either chow or a high-fat diet (HFD)
for 6 weeks were treated with ApoB ASO in doses ranging from 10 to
50 mg/week for an additional 3 weeks, while continuing their diets, at
which time apoB and TG secretion were measured. The doses were
chosen from preliminary studies where 200 or 100 mg/week of ApoB
ASO significantly reduced both TG and apoB secretion in chow-fed mice
(fig. S3).
In the titration experiment, ApoBASO reduced hepatic ApoBmRNA
levels in both groups of mice in a dose-dependent manner, with thewww.Sciencresponse more pronounced in the HFD-fed mice (Fig. 3A), similar to
the results of Lee et al., who conducted experiments with the same
ASO in mice on chow or HFD (10). Relevant to this experiment is
the evidence that ApoB ASO does not significantly alter ApoB mRNA
levels after 2 weeks of treatment (13) in the small intestine, and al-
though it does lower ApoB mRNA after 6 to 8 weeks of treatment,
APOB protein is not altered at those times (10, 13). The effects of ASO
treatment on apoB and TG secretion demonstrated different patterns
in chow- versus HFD-fed mice. Whereas apoB secretion was unaffected
by apoB ASO at the doses administered in the chow-fed mice, it was
inhibited in a stepwise, dose-dependent manner in the HFDmice (Fig.
3B). Furthermore, apoB ASO had modest, non–dose-related effects on
TG secretion in the chow-fed mice, but caused greater reductions of
TG secretion in the HFD mice with a clear trend for dose responsive-
ness (Fig. 3C). The hepatic TG concentration in chow-fed mice receiv-
ing control ASO was 159 ± 33 mg/mg protein and, as expected, much
higher (625 ± 207 mg/mg protein) in the HFD group on control ASO
(P < 0.001, by unpaired t test).
Hepatic steatosis in the HFD group was associated with greater
absolute rates of secretion of newly synthesized apoB in the control
ASO-treated mice compared to chow-fed control ASO-treated mice
(fig. S4). ApoB ASO treatment did not affect expression of the genes
for Ldlr, Idol, or Pcsk9 (fig. S5). Furthermore, ApoB ASO treatmentTable 3. ApoB kinetics. The effects of mipomersen on apoB metabolism
were determined from 17 kinetic studies at the end of the placebo and
mipomersen treatment periods. Absolute values for the placebo and mipo-
mersen periods are shown. If the data were found to be normally distrib-
uted by the Kolmogorov-Smirnov test, they are presented as means (±SD),and statistical analyses were performed on percent change for each
endpoint on mipomersen from placebo using paired t tests. If the data
were not normally distributed, the median and interquartile values (in
parentheses) are shown for percent change, and the Wilcoxon rank-sum
test was performed to test for significance.Parameter PlaceboeTranslationalMediMipomersencine.org 27 January 2016Change
(%)Vol 8 Issue 323 323raP valueVLDL apoB FCR (pools/day) 7.6 (3.6) 9.9 (4.6) 23.0
(−7.4, 55.6)0.023VLDL apoB PR (mg kg−1 day−1) 21.7 (11.3) 19.0 (10.9) −17.6
(−32.7, −0.9)0.15VLDL to IDL (% conversion)* 70.2 (24.2) 58.2 (24.5) −12.1 0.09IDL apoB FCR (pools/day) 5.5 (3.5) 5.8 (3.6) 11.1 0.30IDL apoB PR (mg kg−1 day−1) 15.0 (8.1) 10.2 (6.9) −32.7
(−53.5, −5.7)0.05IDL to LDL (% conversion)* 76.2 (23) 74.4 (26) −1.7 0.84LDL apoB FCR (pools/day) 0.52 (0.14) 0.65 (0.19) 29.7 <0.001LDL apoB PR (mg kg−1 day−1) 12.7 (4.6) 8.8 (3.1) −26.5 0.001Direct LDL PR (mg kg−1 day−1)† 2.6 (3.5) 2.2 (1.5) 0.0
(−0.8, 1.5)0.89LDL apoB PR from direct LDL secretion (%)* 21.3 (22) 26.8 (18) 5.5 0.38Total apoB PR (sum VLDL PR and direct LDL PR) (mg kg−1 day−1) 24.3 (11.5) 21.3 (10.7) −15.1
(−34.5, −7.4)0.26VLDL TG FCR (pools/hour) 10.5 (7.9) 13.2 (8.4) 46.3 0.03VLDL TG PR (mg kg−1 hour−1) 13.1 (6.4) 13.3 (7.0) 10.0 0.40VLDL TG PR/VLDL apoB PR ratio 22.9 (27.0) 26.2 (37.0) 16.5
(−7.8, 93.2)0.05Plasma VLDL TG/VLDL apoB ratio 14.5 (13.7) 15.3 (9.0) 24.6 0.03*For the percent conversions (VLDL to IDL; IDL to LDL), absolute differences between placebo and mipomersen results were used to test for significance. †Some direct LDL secretion rates
were zero, so no percent change was calculated for this parameter; instead, values are absolute differences.12 4
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 did not alter the level of LDLR protein in the livers of mice on either
diet (fig. S6).
These in vivo data are consistent with greater need to use a larger
proportion of newly synthesized apoB for assembly with TG to secrete
VLDL when there is steatosis. In this situation, therefore, any reduc-
tion of apoB synthesis will result in decreased apoB secretion. Indeed,
an exploratory analysis of the relationship between baseline VLDL
apoB production and the decrease in VLDL apoB on mipomersen in
the human study indicated just such a relationship, although the cor-
relation did not achieve significance (fig. S7).www.SciencDISCUSSION
Mipomersen is a second-generation ApoB ASO that inhibits the syn-
thesis of apoB (13, 28). In a phase 1 study, treatment with 50 to 400 mg
of mipomersen injected subcutaneously weekly produced dose-dependent
reductions in plasma LDL-C and apoB concentrations (29). On the basis
of those results and phase 2 studies (18, 19), a dose of 200 mg per
week, by subcutaneous injection, was chosen for further development
and was the dose approved by the FDA for treatment of patients with
homozygous familial hypercholesterolemia (9). The phase 1 and 2 dataFig. 2. Effects of siRNA-mediated knockdown of APOB on apoB secre-
tion in human HepG2 cells. (A) APOB siRNA (10 nM) inhibits the synthesis
cells transfected as in (B), and apoB synthesis and secretion analyzed as
in (A). (F) Efficiency of apoB secretion as a function of APOB siRNAand secretion of apoB in HepG2 cells. HepG2 cells were transfected with
10 nM APOB or 10 nM irrelevant control (Con) siRNA for 2 days, radiolabeled
continuously with [35S]methionine/cysteine for 2 hours, and radioactivity
[counts per minute (CPM)] in cellular or media apoB was determined.
(B) APOB siRNA knocks down APOB mRNA in a dose-dependent manner.
HepG2 cells were transfected at varying doses of APOB siRNA for 2 days.
Total RNA was extracted and APOBmRNA levels were analyzed by quan-
titative polymerase chain reaction (qPCR). (C) APOB siRNA reduces initial
synthesis rates of apoB in a dose-dependent manner. Cells were labeled
with [35S]methionine/cysteine for 10 min and chased for 10 min with or
without proteasome inhibitor ALLN pretreatment for 1 hour. (D and E)
The effect of APOB siRNA doses on cellular and secreted apoB in HepG2knockdown. Efficiency was defined as the percentage of apoB secreted
into the medium compared with the amount of total newly synthesized
apoB (cellular and secreted apoB over 2 hours). (G and H) Cellular and
secreted apoB in HepG2 cell culture after treatment with an MTP inhibitor
(MTPI) for 1 hour (before steady-state labeling for 2 hours). (I) Efficiency
of apoB secretion as a function of MTP inhibition. Data were plotted
using the cell and secreted apoB data, as described in (F). All data are
mean percentage of control [siRNA (1 nM) in (B) to (F); dimethyl sulfoxide
(DMSO) in (G) to (I)] ± SD (n = 3). *P < 0.05; **P < 0.01 versus respective
control, unless otherwise noted, one-way analysis of variance (ANOVA)
followed by post hoc comparisons using the Fisher LSD (least significant
difference) method.eTranslationalMedicine.org 27 January 2016 Vol 8 Issue 323 323ra12 5
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 indicated that the 300- and 400-mg weekly doses had greater LDL-C
and apoB-lowering efficacy than the 200-mg weekly dose, which was
the dose used here. Thus, it is reasonable to conclude that the 200-mg
weekly dose results in submaximal reductions in apoB synthesis; this,
we believe, is critical to the interpretation of our results.
As expected, mipomersen significantly reduced plasma levels of
LDL-C and apoB. VLDL, IDL, and LDL apoB concentrations were also
reduced, as were levels of VLDL TG. The reductions in LDL apoB levels
resulted from decreased LDL PRs, but unexpectedly, the fall in LDL PR
did not result from decreased VLDL apoB secretion into plasma, which
was our primary hypothesis. Instead, decreased production of LDL re-
sulted from increased direct clearance of VLDL apoB with less con-
version to IDL, the immediate precursor of LDL. A modest reductionwww.ScienceTranslationalMedicine.org 2in the direct secretion of LDL into plasma
during mipomersen treatment also con-
tributed to the fall in LDL PR. Additionally,
and also unexpectedly, an increase in FCR
contributed to the reduced LDL apoB lev-
els present during mipomersen treatment.
Why would treatment with a drug that
reduces APOB mRNA, thereby reducing
apoB synthesis, not lower VLDL apoB
PR? In vitro studies in a variety of pri-
mary hepatocytes and hepatic cell lines
have demonstrated repeatedly that apoB
is typically synthesized constitutively and
that its assembly into a VLDL and secre-
tion involves the co-translational lipidation
of the nascent polypeptide as it traverses
the ER (17). The latter step plays a crucial
role in determining how much VLDL is
secreted; in the absence of adequate lipids
or MTP activity, co-translational and co-
translocational degradation of apoB re-
sults (17). Additional sites of intracellular
degradation of apoB can also occur dur-
ing or after the assembly of apoB with
lipids (30), adding further complexity to
the secretory process. The extensive post-
transcriptional and posttranslational con-
trol of the assembly and secretion of VLDL
results in a range of secretion from 20 to
70% of newly synthesized apoB from cul-
tured hepatocytes. The relevance of these
cell-based studies to human physiology is
supported by the wide range of secretory
rates of VLDL in normal and hyperlipidemic
individuals, and the ability to alter VLDL
PR in individuals with different diets and
drugs (31, 32).
With these data in mind, we carried
out a series of studies in HepG2 cells
in which we reduced APOB mRNA in
a stepwise fashion with siRNA (26, 27).
Our findings of increased efficiency of
apoB secretion across a range of inhibi-
tion of apoB synthesis strongly support
our in vivo results. For example, if some-one with normal liver TG levels makes 100 apoB molecules per minute
and only needs to secrete 50 VLDL particles (with one apoB per par-
ticle) to maintain hepatic lipid homeostasis, inhibition of synthesis by
40%, to 60 molecules of apoB produced per minute, should allow the
liver to maintain hepatic lipids at pretreatment levels by increasing the
proportion of nascent apoB that is secreted. In contrast, if hepatic lipids
are elevated and a greater percentage of newly synthesized apoB is con-
stantly being secreted as the liver attempts to reduce hepatic TG, inhibit-
ing synthesis of apoB would likely lead to decreased secretion of VLDL.
This is what we observed in HFD-fed mice compared to chow-fed
mice. The HFD mice had steatosis and much higher rates of apoB
secretion when treated with control ASO and had dose-dependent
reductions in apoB secretion when treated with apoB ASO; this was inB
A
C
Fig. 3. Effects of ApoB ASO treatment on apoB and TG secretion in Apobec-1 knockout mice. Chow-
and HFD-fed mice were treated for 3 weeks with ApoB ASO. (A) ApoB mRNA expression was determined
using qPCR of livers from both chow and HFD mice and normalized to liver b-actin mRNA. In each diet
group, irrelevant, control (Ctrl) ASO-treated mRNA levels were set as 100%. (B) Mice were fasted 4 hours
and injected with Tyloxapol and [35S]methionine intravenously. Plasma 35S-labeled apoB levels in CPM
were determined in samples obtained at 120 min after the start of the study. ApoB radioactivity in mice
receiving the irrelevant control ASO was set as 100%. (C) Blood samples were collected at 0, 30, 60, 90, and
120 min for measurement of TG levels. TG secretion rate was determined by the change in plasma TG
concentration between 30 and 120 min after Tyloxapol injection and divided by 1.5. The secretion rate of
the mice receiving irrelevant control ASO was set at 100%. Data in (A) to (C) are means ± SD (n noted on
figure). *P < 0.05 versus control, unless otherwise noted, one-way ANOVA and Tukey’s post hoc test.7 January 2016 Vol 8 Issue 323 323ra12 6
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 marked contrast to what was observed in chow-fed mice. Results of an
exploratory analysis in our subjects provided support for our model of
the role of apoB in maintaining hepatic lipid homeostasis. In our
normolipidemic participants, higher VLDL apoB PRs on placebo
were associated with greater reductions in VLDL apoB secretion on
mipomersen. Further studies of the effects of mipomersen on apoB
metabolism in people with hepatic steatosis and a dyslipidemia char-
acterized by increased VLDL apoB and VLDL TG secretion will be
required to definitively address this important question.
Our second hypothesis, that VLDL TG PR would not be affected
by mipomersen owing to assembly and secretion of larger VLDL, was
supported by our findings of increased ratios of TG to apoB in circu-
lating VLDL and an increased ratio of VLDL TG PR to VLDL apoB PR.
A rigorous examination of this hypothesis, which is supported by
in vitro studies in cultured liver cells that were treated with FAs (33)
and in vivo studies in mice and humans in which hepatic de novo
lipogenesis was increased (20, 34), must await further studies of
mipomersen treatment of hypertriglyceridemic subjects. Plasma and
VLDL TG levels fell despite any change in VLDL TG PR. Our finding
of increased FCRs for VLDL TG in the absence of increases in post-
heparin LpL and HL activities points to previous studies showing
increased efficiency of LpL-mediated lipolysis of larger and more TG-
enriched particles (35). Additionally, we observed an increase in both
the FCR of VLDL apoB and the direct removal of VLDL apoB without
conversion to IDL or LDL. The increased FCR of VLDL apoB could
simply have been the result of a more efficient LpL-mediated lipolysis
of larger VLDL TG or a result of reduced levels of apoC-III we ob-
served during mipomersen treatment. However, that would have re-
sulted in a more rapid and efficient conversion of VLDL to IDL and
LDL, rather than the decreased conversion we observed.
Both apoE and apoC-III affect hepatic removal of VLDL; apoE
levels in plasma were not altered by mipomersen treatment, but the
reductions in apoC-III levels we observed could have resulted in
greater removal of VLDL or their remnants by the liver with less con-
version to IDL. The latter would be more likely if the reduced apoC-III
levels resulted from mipomersen-mediated decreased secretion of the
protein by the liver rather than those lower concentrations being the
result of lower levels of VLDL, IDL, and LDL, which all carry apoC-III.
Further studies will be required to determine if decreased apoB syn-
thesis affects apoC-III synthesis or secretion by the liver.
The reductions in LDL we observed resulted from both decreased
PR due to less conversion of VLDL to IDL and LDL, and a significant
and unexpected increase in LDL FCR. We were unable to discern why
inhibition of hepatic apoB synthesis would lead to an increase in LDL
FCR, which is typically associated with increased levels of hepatic LDL
receptors. However, we did measure plasma PCSK9 concentrations as
a surrogate, because lower PCSK9 levels would mean increased hepatic
LDL receptors available to bind LDL (24). Mipomersen had no effect on
plasma PCSK9 levels in humans. Reduced rates of endogenous choleste-
rol synthesis or intestinal absorption of cholesterol could also lead down-
stream to increased LDLR, but we saw no effects of mipomersen treatment
on the three markers of the whole-body cholesterol metabolism:
lathosterol, campesterol, or b-sistosterol. LDLR, PCSK9, and IDOLmRNA
were unchanged in human HepG2 cells treated with maximally sup-
pressive doses of siRNA. Furthermore, mipomersen did not affect
mRNA levels of the Ldlr, Pcsk9, and Idol, or the level of LDLR protein
in mice. An explanation that is not dependent on the number of LDL
receptors in the liver would be greater affinity of LDL for the samewww.Sciencnumber of receptors; we did see a change in the distribution of LDL
size, in the direction of smaller LDL particles, but small LDLs have
lower affinity for the LDLR. The reductions that occurred in the
numbers of particles in all the large LDL subfractions are consistent,
however, with increased LDLR-mediated clearance. Additionally, the
cholesterol-to-apoB ratio in LDL increased; larger, cholesterol-enriched
LDL is believed to have greater affinity for the LDLR. As noted above,
we observed reductions in apoC-III, which can inhibit the uptake of
LDL by its receptor. However, apoC-III is only carried on a small frac-
tion of LDL, and the changes we observed in apoC-III are unlikely to
explain the significant increase in LDL FCR with mipomersen treat-
ment. Overall, we do not have a clear explanation for the increased
LDL apoB FCR during mipomersen treatment.
We understand that the results of mipomersen treatment of hu-
mans with homozygous familial hypercholesterolemia suggest that the
LDL receptor is not needed for efficacy of this agent (9). Studies of
apoB metabolism in homozygous familial hypercholesterolemia with
null mutations have demonstrated increased secretion of apoB lipo-
proteins (36, 37); in our model, mipomersen inhibition of apoB syn-
thesis would decrease apoB secretion in those individuals. In
summary, our study of the effects of mipomersen in healthy subjects,
supported by our studies in HepG2 cells and mice, provides new and
unique insights into mechanisms for the maintenance of hepatic lipid
homeostasis when apoB synthesis is reduced. Our results indicate that
inhibition of apoB synthesis should remain a target for therapies to
reduce levels of all atherogenic lipoproteins.MATERIALS AND METHODS
Study design
This was a single blind, two-period, linear, placebo-controlled,
phase 1 study in healthy volunteers. The first primary hypothesis
was that mipomersen, administered at a dose of 200 mg weekly, would
significantly reduce the PR of VLDL apoB. The second hypothesis was
that there would be an increase in the efficiency of VLDL TG fractional
clearance from the circulation during mipomersen treatment. Explora-
tory hypotheses included that there would not be a change in VLDL
TG production; that there would not be a change in direct removal of
VLDL apoB from the circulation; that LDL apoB production would be
reduced, but fractional removal would not be affected; that hepatic
DNL would not be affected; and that FA oxidation in the liver, as es-
timated by measurement of circulating b-hydroxybutyrate, would not
change during mipomersen treatment. The primary endpoint was the
percent change in VLDL apoB PR from the end of placebo to the end
of mipomersen treatment. The sample size calculation indicated that
16 subjects would provide 80% power to detect a 20% reduction in
VLDL apoB PR, on the basis of a paired t test with a 5% type I error
rate, assuming an SD of about 6 mg kg−1 day−1 as observed in previous
research (38, 39) and an expected VLDL apoB PR of about 25 mg kg−1
day−1 at the end of the placebo period. Additional details of the study
protocol are in the Supplementary Materials and fig. S1.
Human volunteers
All subjects signed informed consent. For screening, see the Supple-
mentary Materials. Subjects were nonsmokers, were of ages 18 to 75 years,
had a body mass index (BMI) of less than 38 kg/m2, and were not on
any lipid-altering medications. All participants had blood glucoseeTranslationalMedicine.org 27 January 2016 Vol 8 Issue 323 323ra12 7
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 <115 mg/dl, TG <170 mg/dl, and LDL-C >100 mg/dl and <160 mg/dl
if they had more than two cardiovascular risk factor. Subjects who met
the eligibility criteria were instructed to follow an American Heart
Association–recommended diet. After an additional week, subjects
returned to the Irving Institute for Clinical and Translational Research
(IICTR) for study randomization and fasting measurements of plasma
lipids, a chemistry panel, hematology studies, and vital signs.
Mathematical modeling of the apoB and TG enrichment data
ApoB kinetics in VLDL, IDL, and LDL were estimated using the leu-
cine and phenylalanine enrichment data from the constant infusion
and the bolus injection, respectively (38, 39). The kinetics of VLDL
TG were analyzed using the enrichment data generated by the
injection of D5-glycerol. Mathematical modeling is described in the
Supplementary Methods.
In vitro studies of APOB knockdown and inhibition of MTP
activity in HepG2 cells
HepG2 cells were obtained from American Type Culture Collection
and cultured in a growth medium of Dulbecco’s modified Eagle’s me-
dium (high glucose, 5% antibiotics, and 10% fetal bovine serum).
Transfection of HepG2 cells and metabolic labeling to measure the
secretion and synthesis of apoB were performed with both steady-state
and pulse-chase labeling protocols as described previously in our lab-
oratory; details are provided in the Supplementary Materials (40, 41).
In vivo studies of ApoB knockdown in mice
All animal experiments were approved by the Columbia University
Institutional Animal Care and Use Committee. Details regarding the
mice are in the Supplementary Materials. After 6 weeks on HFD, Apobec-
1 knockout mice were started on treatment with mouse control ASO
(ISIS #141923) or a second-generation mouse apoB ASO (Ionis Pharma-
ceuticals #147764) for 3 weeks; these reagents were provided by Ionis
Pharmaceuticals. Mice remaining on chow diet were started on ASO
treatment at the same age as the mice on HFD. The ApoB ASO was
administered at different doses (10, 25, or 50 mg/week) mixed with con-
trol ASO to give equal amounts of ASO in each injection. At the end of 3
weeks of ASO treatment, mice were fasted for 4 hours, and TG and
apoB secretion was measured by intravenously injecting Tyloxapol
(500 mg/kg) (T8761-50G, Sigma-Aldrich) and 200 mCi per mouse
[35S]methionine (1175 Ci/mmol; PerkinElmer Life Sciences) as de-
scribed previously (42).
Statistical analysis
The Wilcoxon signed-rank test and the paired t test were used to test
the hypothesis that there was no change between the first and second
turnover studies. The Kolmogorov-Smirnov statistic tested the hypo-
thesis that the percent/nominal change was normally distributed. For the
in vitro cell and in vivo mouse studies, all data are presented as means ±
SD. Differences in the means among multiple groups were compared
for significance using a one-way ANOVA followed by individual com-
parisons when appropriate. P < 0.05 was considered significant.SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/full/8/323/323ra12/DC1
Methods
Fig. S1. Study flow diagram.www.SciencFig. S2. No changes in LDLR, IDOL, or PCSK9 mRNA levels in HepG2 cells after knockdown
of APOB.
Fig. S3. ApoB ASO inhibits hepatic secretion of TG and apoB frommice on either chow or HFD diet.
Fig. S4. ApoB secretion is increased in Apobec-1 knockout mice on HFD.
Fig. S5. ApoB siRNA treatment does not affect expression of Ldlr, Idol, or Pcsk9 in mouse livers.
Fig. S6. Hepatic LDL receptor was not affected by ApoB ASO.
Fig. S7. Relationship between mipomersen-induced reductions in VLDL apoB PR and baseline
VLDL PR.
Table S1. Participant information.
Table S2. Effect of mipomersen on apoB lipoprotein particle number by ion mobility analysis.
Table S3. Effect of mipomersen on apoB lipoprotein size distribution by ion mobility analysis.
Table S4. Effect of mipomersen on LDL size subfraction particle numbers by ion mobility analysis.
Table S5. Markers of cholesterol synthesis and absorption.
Table S6. Hepatic lipase, lipoprotein lipase, FFA, and b-hydroxybutyrate levels.
Table S7. Individual participant apoB kinetics of VLDL, IDL, LDL, and VLDL TG FCR.
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cell lines demonstrated how the liver compensates for reduced apoB synthesis to potentially avoid
from the liver. The direct clearance of VLDL led to reduced production of LDL. Studies in mice and 
secretionby increasing clearance of both of these vessel-clogging lipoproteins rather than reducing their 
(VLDL),volunteers that the drug reduced levels of LDL and its precursor, very low density lipoproteins 
how mipomersen works exactly in humans is unclear. Reyes-Soffer and colleagues found in healthy
(LDL) in patients with high cholesterol by targeting apolipoprotein B (apoB) synthesis. Although safe, 
Mipomersen is an FDA-approved antisense oligonucleotide that lowers low density lipoprotein
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